{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:17:56Z","timestamp":1790835476487,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005302","name":"Alexander S. Onassis Public Benefit Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["847551"],"award-info":[{"award-number":["847551"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.autrev.2025.103934","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:20:00Z","timestamp":1757542800000},"page":"103934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of Sphingosine-1-phosphate receptor modulator treatment on leukocyte subsets across different clinical indications: A systematic review"],"prefix":"10.1016","volume":"24","author":[{"given":"Dimitrios","family":"Nikolakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Grootjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen G.H.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103934_bb0005","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103934_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-022-00784-6","article-title":"Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases","volume":"18","author":"Burg","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103934_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2025.103934_bb0025","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000839","article-title":"Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103934_bb0030","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103934_bb0035","first-page":"819","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study, lancet","volume":"5","author":"Feagan","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103934_bb0040","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103934_bb0045","doi-asserted-by":"crossref","unstructured":"Moola S, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk . In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020., in: Editor (Ed.)^(Eds.), Book.","DOI":"10.46658\/JBIRM-17-06"},{"key":"10.1016\/j.autrev.2025.103934_bb0050","doi-asserted-by":"crossref","unstructured":"T.H.S. Barker, Jennifer C; Sears, Kim, Klugar, Miloslav, Tufanaru, Catalin, Leonardi-Bee, Jo, Aromataris, Edoardo, Munn, Zachary. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evidence Synthesis 21(3):p 494\u2013506, March 2023. | DOI: 10.11124\/JBIES-22-00430 in: Editor (Ed.)^(Eds.), Book, pp.","DOI":"10.11124\/JBIES-22-00430"},{"key":"10.1016\/j.autrev.2025.103934_bb0055","unstructured":"Fingolimod, in: Editor (Ed.)^(Eds.), Book Fingolimod, pp."},{"key":"10.1016\/j.autrev.2025.103934_bb0060","unstructured":"Etrasimod, in: Editor (Ed.)^(Eds.), Book Etrasimod, pp."},{"key":"10.1016\/j.autrev.2025.103934_bb0065","unstructured":"Siponimod, in: Editor (Ed.)^(Eds.), Book Siponimod, pp."},{"key":"10.1016\/j.autrev.2025.103934_bb0070","unstructured":"Ceralifimod, in: Editor (Ed.)^(Eds.), Book Ceralifimod, pp."},{"key":"10.1016\/j.autrev.2025.103934_bb0075","unstructured":"Clinicaltrial.gov, Ceralifimod, in: Editor (Ed.)^(Eds.), Book Ceralifimod, pp."},{"key":"10.1016\/j.autrev.2025.103934_bb0080","unstructured":"Ozanimod, in: Editor (Ed.)^(Eds.), Book Ozanimod, pp."},{"key":"10.1016\/j.autrev.2025.103934_bb0085","unstructured":"FDA, Ozanimod label, Ozanimod label."},{"key":"10.1016\/j.autrev.2025.103934_bb0090","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab201","article-title":"A phase II, multicentre, randomised, double-blind, placebo-controlled study to evaluate safety, tolerability, and efficacy of amiselimod in patients with moderate to severe active crohn's disease","volume":"16","author":"D'Haens","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2025.103934_bb0095","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458517728343","article-title":"Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103934_bb0100","first-page":"e21","article-title":"Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial, lancet","volume":"7","author":"Askanase","year":"2025","journal-title":"Rheumatol"},{"key":"10.1016\/j.autrev.2025.103934_bb0105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2012.03.007","article-title":"Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients","volume":"246","author":"Moberly","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0110","unstructured":"CS-0777, in: Book CS-0777."},{"key":"10.1016\/j.autrev.2025.103934_bb0115","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/cts.13227","article-title":"Single-dose of LC51-0255, a selective S1P(1) receptor modulator, showed dose-dependent and reversible reduction of absolute lymphocyte count in humans","volume":"15","author":"Won Lee","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2025.103934_bb0120","unstructured":"Clinicaltrial.gov, LC51\u20130255, in: Book LC51\u20130255."},{"key":"10.1016\/j.autrev.2025.103934_bb0125","unstructured":"Clinicaltrial.gov, Mocravimod, Mocravimod."},{"key":"10.1016\/j.autrev.2025.103934_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000509393","article-title":"Double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis","volume":"5","author":"Radeke","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.autrev.2025.103934_bb0135","unstructured":"Clinicaltrial.gov, Mocravimod, Mocravimod."},{"key":"10.1016\/j.autrev.2025.103934_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.10.029","article-title":"Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy","volume":"29","author":"Dertschnig","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.autrev.2025.103934_bb0145","unstructured":"FDA, Ponesimod label, Ponesimod label."},{"key":"10.1016\/j.autrev.2025.103934_bb0150","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/01.TP.0000121761.02129.A6","article-title":"FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation","volume":"79","author":"Tedesco-Silva","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2025.103934_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1039","article-title":"The effect of Fingolimod on patients with moderate to severe COVID-19","volume":"11","author":"Teymouri","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.autrev.2025.103934_bb0160","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/cns.12793","article-title":"Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator","volume":"24","author":"Angerer","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2025.103934_bb0165","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mus.25733","article-title":"Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability","volume":"56","author":"Berry","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2025.103934_bb0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2016.03.012","article-title":"Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFbeta in patients with multiple sclerosis","volume":"70","author":"Blumenfeld","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103934_bb0175","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.intimp.2006.08.018","article-title":"Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients","volume":"7","author":"Bohler","year":"2007","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0180","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/ndt\/gfg599","article-title":"FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors","volume":"19","author":"Bohler","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2025.103934_bb0185","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/01.TP.0000120539.94629.6A","article-title":"FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ t lymphocytes","volume":"77","author":"B\u00f6hler","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2025.103934_bb0190","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1034\/j.1600-6143.2003.00130.x","article-title":"Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients","volume":"3","author":"Budde","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2025.103934_bb0195","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/1352458514551456","article-title":"Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients","volume":"21","author":"Chiarini","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103934_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study","volume":"9","author":"Claes","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103934_bb0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2018.08.002","article-title":"Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo","volume":"96","author":"Dominguez-Villar","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103934_bb0210","doi-asserted-by":"crossref","first-page":"12905","DOI":"10.1038\/s41598-017-13376-2","article-title":"S1P(1) deletion differentially affects TH17 and regulatory T cells","volume":"7","author":"Eken","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103934_bb0215","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2019.00217","article-title":"Fingolimod Alters tissue distribution and cytokine production of human and murine innate lymphoid cells","volume":"10","author":"Eken","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0220","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1399-3046.2011.01498.x","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants","volume":"15","author":"Ettenger","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.autrev.2025.103934_bb0225","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamaneurol.2014.1065","article-title":"Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study","volume":"71","author":"Fu","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0230","doi-asserted-by":"crossref","first-page":"18315","DOI":"10.1073\/pnas.1416166111","article-title":"Impact of an immune modulator fingolimod on acute ischemic stroke","volume":"111","author":"Fu","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2025.103934_bb0235","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103934_bb0240","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41598-019-57114-2","article-title":"Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis","volume":"10","author":"Ghadiri","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103934_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acn3.155","article-title":"Fingolimod treatment promotes regulatory phenotype and function of B cells","volume":"2","author":"Grutzke","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228380","article-title":"Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets","volume":"15","author":"Hjorth","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103934_bb0255","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4049\/jimmunol.1003823","article-title":"Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients","volume":"187","author":"Johnson","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0260","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.3389\/fimmu.2018.02669","article-title":"Real world lab data: patterns of lymphocyte counts in Fingolimod treated patients","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0265","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13311-020-00975-7","article-title":"Differential effects of Fingolimod and Natalizumab on B cell repertoires in multiple sclerosis patients","volume":"18","author":"Kowarik","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2025.103934_bb0270","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103934_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577065","article-title":"Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients","volume":"337","author":"Kurtuncu","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0280","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200100","article-title":"Increased NLRP3 Inflammasome activation and Pyroptosis in patients with multiple sclerosis with Fingolimod treatment failure","volume":"10","author":"Malhotra","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103934_bb0285","article-title":"Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: the FLUENT study","volume":"8","author":"Mao-Draayer","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.autrev.2025.103934_bb0290","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12974-015-0460-z","article-title":"Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation","volume":"12","author":"Mazzola","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2025.103934_bb0295","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103934_bb0300","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","article-title":"Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients","volume":"69","author":"Mehling","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0305","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e3181ebdd64","article-title":"Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis","volume":"75","author":"Mehling","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103934_bb0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2017.10.009","article-title":"Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis","volume":"187","author":"Miyazaki","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113025","article-title":"Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients","volume":"9","author":"Muls","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103934_bb0320","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/1352458514523496","article-title":"Differential effects of fingolimod on B-cell populations in multiple sclerosis","volume":"20","author":"Nakamura","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103934_bb0325","doi-asserted-by":"crossref","first-page":"29699","DOI":"10.1038\/srep29699","article-title":"B lymphocytes in multiple sclerosis: Bregs and BTLA\/CD272 expressing-CD19+ lymphocytes modulate disease severity","volume":"6","author":"Piancone","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103934_bb0330","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103934_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104484","article-title":"Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators","volume":"70","author":"Sabatino","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103934_bb0340","article-title":"Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod","volume":"10","author":"Song","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103934_bb0345","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cns.12548","article-title":"Baseline differences in minor lymphocyte subpopulations may predict response to Fingolimod in relapsing-remitting multiple sclerosis patients","volume":"22","author":"Teniente-Serra","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2025.103934_bb0350","series-title":"Book Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation., J Neuroinflammation","article-title":"Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation., in: Editor (Ed.)^(Eds.)","author":"Thomas","year":"2017"},{"key":"10.1016\/j.autrev.2025.103934_bb0355","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ana.25352","article-title":"Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow","volume":"84","author":"Tian","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0360","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.016371","article-title":"Combination of the immune modulator Fingolimod with Alteplase in acute ischemic stroke: a pilot trial","volume":"132","author":"Zhu","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103934_bb0365","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/jcph.513","article-title":"Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm","volume":"55","author":"Krosser","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0370","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41577-019-0194-8","article-title":"Functional interactions between innate lymphoid cells and adaptive immunity","volume":"19","author":"Sonnenberg","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0375","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.msard.2019.06.016","article-title":"Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire","volume":"34","author":"Blumenfeld-Kan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103934_bb0380","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.1379","article-title":"Safety pharmacokinetics, and pharmacodynamics of etrasimod: single and multiple ascending dose studies in healthy adults","volume":"13","author":"Lee","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.autrev.2025.103934_bb0385","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.14309\/01.ajg.0000722976.59079.27","article-title":"P045 effect of Etrasimod on circulating lymphocyte subsets: data from a randomized phase 1 study in healthy Japanese and Caucasian men","volume":"115","author":"Kiyomi","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103934_bb0390","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/j.jid.2022.05.866","article-title":"Effect of etrasimod on circulating lymphocyte subsets in atopic dermatitis patients","volume":"142","author":"Ryan","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103934_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx002.114","article-title":"Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator","volume":"11","author":"Lee","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.autrev.2025.103934_bb0400","series-title":"UEGW 2022","article-title":"Etrasimod reduces adaptive immune cells in the periphery in UC","author":"Danese","year":"2022"},{"key":"10.1016\/j.autrev.2025.103934_bb0405","doi-asserted-by":"crossref","first-page":"i701","DOI":"10.1093\/ecco-jcc\/jjac190.0705","article-title":"Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Siegmund","year":"2023","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.autrev.2025.103934_bb0410","doi-asserted-by":"crossref","first-page":"S-794","DOI":"10.1016\/S0016-5085(24)02310-2","article-title":"Su1746 SPHINGOSINE-1-phosphate receptor blockade with ETRASIMOD ALTERS lymphocyte trafficking in CROHN'S disease: insights from high-dimensional phenotypic mapping","volume":"166","author":"Nikolakis","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103934_bb0415","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0420","series-title":"Book Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS","article-title":"Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS","author":"Bar-Or","year":"2017"},{"key":"10.1016\/j.autrev.2025.103934_bb0425","volume":"5","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103934_bb0430","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1007\/s00415-024-12362-9","article-title":"Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications","volume":"271","author":"Spiezia","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0435","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpdd.98","article-title":"Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers","volume":"3","author":"Xu","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.autrev.2025.103934_bb0440","series-title":"Effect of Ozanimod on circulating leukocyte subtypes in patients with relapsing multiple sclerosis and comparison with healthy volunteers, presented at the 37th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","author":"Harris","year":"2021"},{"key":"10.1016\/j.autrev.2025.103934_bb0445","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s10620-024-08391-z","article-title":"Ozanimod differentially impacts circulating lymphocyte subsets in patients with moderately to severely active Crohn's disease","volume":"69","author":"Harris","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2025.103934_bb0450","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with Ozanimod, a novel, selective Sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0455","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/0961203320966385","article-title":"Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study","volume":"29","author":"Tanaka","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103934_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103934_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001261","article-title":"Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus","volume":"6","author":"Strasser","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103934_bb0470","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1177\/0091270011408728","article-title":"Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator","volume":"52","author":"Moberly","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.930615","article-title":"Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects","volume":"13","author":"Hwang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0480","series-title":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT (MO-TRANS)","article-title":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT (MO-TRANS)","author":"NCT05429632","year":"2022"},{"key":"10.1016\/j.autrev.2025.103934_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2023.104719","article-title":"Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"388-389","author":"Dertschnig","year":"2023","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0490","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/DDDT.S120399","article-title":"Effects of multiple-dose ponesimod, a selective S1P(1) receptor modulator, on lymphocyte subsets in healthy humans","volume":"11","author":"Jurcevic","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.autrev.2025.103934_bb0495","doi-asserted-by":"crossref","first-page":"127-35","DOI":"10.1016\/j.clim.2014.02.001","article-title":"Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations","volume":"151","author":"Miyazaki","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103934_bb0500","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/ecco-jcc\/jjad174","article-title":"Ozanimod-exposed patients with ulcerative colitis undergoing Total colectomy exhibit unique lymph node histological changes","volume":"18","author":"Cohen","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103934_bb0505","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical program","volume":"18","author":"Regueiro","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2025.103934_bb0510","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0515","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0520","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"J.A. Cohen, B. Khatri, F. Barkhof, G. Comi, H.P. Hartung, X. Montalban, J. Pelletier, T. Stites, S. Ritter, P. von Rosenstiel, D. Tomic, L. Kappos and T.S. Group","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103934_bb0525","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103934_bb0530","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with Teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2025.103934_bb0535","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L. Zhang-Auberson, P. Burtin and F.S. Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103934_bb0540","author":"Mao-Draayer"},{"key":"10.1016\/j.autrev.2025.103934_bb0545","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103934_bb0550","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.18914","article-title":"Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2025.103934_bb0555","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fphar.2017.00296","article-title":"Sphingosine 1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis?","volume":"8","author":"Vestri","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103934_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with Sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: insights from a pooled analysis of 15 randomised controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:30:17Z","timestamp":1765024217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1568997225001958"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103934","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Sphingosine-1-phosphate receptor modulator treatment on leukocyte subsets across different clinical indications: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103934"}}